Congress probes celebrity endorsers

Share this article:

Congress is investigating the use of celebrity endorsements in pharmaceutical advertising—starting with a “celebrity doctor,” artificial heart inventor Dr. Robert Jarvik.

In a letter to Pfizer honcho Jeff Kindler, Michigan Democrats John Dingell, chairman of the House Committee on Energy and Commerce, and Bart Stupak, chairman of the House Subcommittee on Oversight and Investigations, announced that they are looking into Pfizer's use of Dr. Jarvik in ads for Lipitor.

“We are concerned that consumers may misinterpret the health claims of a prescription drug promoted in a (DTC) advertisement utilizing a celebrity physician,” Dingell wrote, adding that consumers might also overestimate the qualifications of Dr. Jarvik “given that he may not be a practicing physician with a valid license in any state.”

Dr. Jarvik invented the Jarvik 7, the first successful permanent artificial heart, but is not a practicing physician.

The letter, dated Jan. 7, requested all records pertaining to the campaign and Pfizer's relationship with Dr. Jarvik, including financial records, contractual arrangements, correspondence and scripts for TV and print ads with Jarvik. The committee also requested “any records relating to the veracity of any claims made by Dr. Jarvik” in ads, “including but not limited to his use of Lipitor” and “all records relating to Dr. Jarvik's professional qualifications and why Pfizer chose him as their spokesman for Lipitor.” 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...